Herpes simplex virus hepatitis in mice: effects of treatment with trisodium phosphonoformate.
Clinical isolates of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) induced focal necrotic hepatitis in ICR/Schö mice. The extent of the hepatitis could be considerably reduced by trisodium phosphonoformate (PFA) administered for 3 days in a daily dose of 400-600 mg/kg. The HSV hepatitis in mice could serve as a suitable model for testing antiherpetic drugs.
Ulbricht
A
A
Färber
I
I
Wutzler
P
P
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D017245:Foscarnet; D006524:Hepatitis, Viral, Animal / Q000188:drug therapy* / Q000473:pathology; D006561:Herpes Simplex / Q000188:drug therapy* / Q000473:pathology; D008099:Liver / Q000473:pathology; D051379:Mice; D009336:Necrosis; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000998:Antiviral Agents; D009943:Organophosphorus Compounds; D017245:Foscarnet; D010746:Phosphonoacetic Acid